Researchers at Centre National de la Recherche Scientifique, Université De Picardie Jules Verne and Université Paris-Est Créteil Val de Marne (UPEC) have identified lipid anionic oligosaccharides acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Benobio Co. Ltd. has synthesized novel quinizarin derivatives acting as bromodomain and extra-terminal (BET) protein inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).

University of Western Australia has disclosed 3,4-methylenedioxymethamphetamine (MDMA) analogues acting as dopamine transporter (DAT) and/or norepinephrine transporter (NET) and/or serotonin transporter (SERT) modulators reported to be useful for the treatment of neurological and psychiatric disorders.

Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) targeting moiety reported to be useful for the treatment of cancer.

St. Jude Children’s Research Hospital has divulged molecular glue degraders comprising cereblon (CRBN) binding agents covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and/or DNA-binding protein ikaros (IKZF1) targeting moiety acting as GSPT1 and/or IKZF1 degradation and GSPT1 and/or IKZF1/CRBN interaction inducers reported to be useful for the treatment of cancer.

GSK plc has identified pyrazine compounds reported to be useful for the treatment of malaria infection by Plasmodium falciparum.

Novartis AG has synthesized naphthyridinone derivatives acting as K(ir) 3.1/3.4 (GIRK1/4; KCNJ3/5) IKACh channel blockers reported to be useful for the treatment of bradyrhythmic arrhythmia, bradycardia, atrial fibrillation, heart block, hypotension, primary aldosteronism, sick sinus syndrome and vasovagal syncope, among others.

Remix Therapeutics has disclosed compounds acting as RNA splicing modulators reported to be useful for the treatment of cancer and Huntington’s disease.

Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors have been reported by Shanghai Jemincare Pharmaceuticals Co. Ltd. to be potentially useful for the treatment of cancer, fibrosis, inflammation, pain, neurodegeneration, autoimmune, metabolic and cardiovascular disorders, among others.

Several Lario Therapeutics Ltd. patents describe new voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) antagonists reported to be useful for the treatment of neurodegeneration, epilepsy, Parkinson’s disease, cerebral vasospasm, pain, CDKL5 deficiency, endocrine and neurodevelopmental disorders, among others.